Study guide

2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

Key Takeaways Explain This Topic AI

The nerve action potential is an all-or-none event: voltage-gated Na+ channels open at threshold (about -55 mV), then inactivate while delayed-rectifier K+ channels repolarize the membrane.

Myelin raises membrane resistance and lowers capacitance, so impulses jump between nodes of Ranvier (saltatory conduction) at up to about 120 m/s.

Myasthenia gravis attacks postsynaptic nicotinic receptors (decrement on 3-Hz stimulation); Lambert-Eaton syndrome attacks presynaptic P/Q calcium channels (increment after exercise, linked to small cell lung cancer).

Skeletal muscle couples DHPR to RyR1 mechanically, cardiac muscle needs trigger calcium for calcium-induced calcium release, and smooth muscle uses calmodulin and myosin light-chain kinase.

Malignant hyperthermia is an RYR1 disorder triggered by volatile anesthetics or succinylcholine, and dantrolene is the antidote.

Last updated: October 2026

Why this area matters

The neurophysiology area (17 items) begins with "nerve stimulus and action potential, nerve impulse conduction". Muscle physiology runs through cardiology, anesthesia and pharmacology items. Expect to:

  • reason from channel behavior to a clinical sign, such as weakness in hyperkalemia or demyelination;
  • tell apart the three classic neuromuscular junction disorders;

explain why the three muscle types respond differently to calcium-channel blockers, nitrates and anesthetic agents.

Action Potential Phases & Saltatory Conduction

An action potential is an all-or-none, regenerative reversal of membrane polarity in excitable cells (neurons and myocytes).

Phases of the Fast Action Potential (Nerve and Skeletal Muscle)

Resting Phase : Membrane resting at − 70 to − 90 mV -70\text{ to }-90\text{ mV} − 70 to − 90 mV , dominated by K + K^+ K + leak conductance.

Threshold and rapid depolarization (upstroke) : When a local graded potential depolarizes the axon initial segment or motor end-plate to threshold (approximately − 55 mV -55\text{ mV} − 55 mV ), voltage-gated sodium channels ( N a v 1 Nav1 N a v 1 ) open rapidly. The outer activation gate ( m m m -gate) swings open, producing a massive inward N a + Na^+ N a + current ( I N a I_{Na} I N a ​ ) that rapidly drives the membrane toward + 30 to + 40 mV +30\text{ to }+40\text{ mV} + 30 to + 40 mV (approaching E N a E_{Na} E N a ​ ). This positive feedback cycle is termed the Hodgkin cycle.

Overshoot and sodium inactivation : Near peak voltage, the inner inactivation gate ( h h h -gate, the "ball-and-chain" peptide loop) swings shut, halting N a + Na^+ N a + influx.

Repolarization : Voltage-gated delayed-rectifier potassium channels ( K v Kv K v ) open with a slight kinetic delay. Potassium rapidly exits the cell down its chemical gradient ( I K I_K I K ​ ), driving membrane potential back down toward negative values.

Afterhyperpolarization (undershoot) : Because delayed-rectifier K + K^+ K + channels close slowly, potassium permeability remains transiently higher than at rest, dipping membrane potential down toward E K E_K E K ​ ( − 90 mV -90\text{ mV} − 90 mV ) before restoring baseline RMP.

Refractory Periods

Absolute Refractory Period (ARP) : Extends from the start of the upstroke until repolarization is well under way. During ARP, virtually all voltage-gated N a + Na^+ N a + channels are either actively open or locked in the inactivated state ( h h h -gate closed). No stimulus, regardless of intensity, can trigger another action potential. This enforces unidirectional propagation and sets an upper limit on firing frequency.

Relative Refractory Period (RRP) : Follows the ARP. A fraction of N a + Na^+ N a + channels have reset from the inactivated state to the closed-resting state ( h h h -gate open, m m m -gate closed), but delayed-rectifier K + K^+ K + conductance remains high. An action potential can be triggered, but only by a suprathreshold stimulus, and the resulting spike exhibits a reduced rate of rise and lower peak amplitude.

Determinants of Conduction Velocity & Cable Theory

Conduction velocity along a cylindrical axon depends on its passive electrical cable properties:

Length Constant (Space Constant, λ \lambda λ ) : λ = r m r i \lambda = \sqrt{\frac{r_m}{r_i}} λ = r i ​ r m ​ ​ ​ Where r m r_m r m ​ is membrane resistance and r i r_i r i ​ is internal axial cytoplasmic resistance. A larger λ \lambda λ means electrotonic current spreads farther along the core before dissipating across the membrane, speeding propagation. Increasing axon diameter lowers r i r_i r i ​ substantially, increasing λ \lambda λ .

Time Constant ( τ \tau τ ) : τ = r m ⋅ C m \tau = r_m \cdot C_m τ = r m ​ ⋅ C m ​ Where C m C_m C m ​ is membrane capacitance. A lower τ \tau τ allows the membrane to charge and discharge more rapidly, accelerating conduction.

Saltatory vs. Continuous Conduction

Unmyelinated Fibers (e.g., autonomic postganglionic fibers, pain/temperature C fibers): Continuous conduction. Every adjacent patch of axolemma must undergo depolarization and N a v Nav N a v channel activation. Conduction velocity is slow ( 0.5 – 2.0 m/s 0.5\text{--}2.0\text{ m/s} 0.5 – 2.0 m/s ).

Myelinated Fibers (e.g., A α A\alpha A α motor neurons, A β A\beta A β sensory afferents): Wrapped by Schwann cells (peripheral nervous system) or oligodendrocytes (central nervous system) in concentric layers of lipid-rich myelin. Myelin increases membrane resistance ( r m r_m r m ​ ) by 100-fold and dramatically decreases membrane capacitance ( C m C_m C m ​ ). Current flows almost instantaneously through the low-resistance internodal axoplasm, jumping from one unmyelinated node of Ranvier to the next ( saltatory conduction ). Voltage-gated N a v 1.6 Nav1.6 N a v 1.6 channels are densely packed at the nodes ( > 1 , 000 / μ m 2 > 1,000/\mu\text{m}^2 > 1 , 000/ μ m 2 ). Conduction velocity reaches 70 – 120 m/s 70\text{--}120\text{ m/s} 70 – 120 m/s . In demyelinating neuropathies (Guillain-Barré syndrome, Charcot-Marie-Tooth, Multiple Sclerosis), loss of myelin increases capacitance and causes current leakage across the exposed internodal membrane, resulting in conduction block and severe motor weakness.

The Neuromuscular Junction: Transmission & Pathologies

The neuromuscular junction (NMJ) is a specialized chemical synapse between an alpha-motor neuron terminal bouton and the motor end-plate of a skeletal muscle fiber.

Sequence of Neuromuscular Transmission

Presynaptic Action Potential & Calcium Entry : A motor nerve action potential depolarizes the presynaptic terminal, opening voltage-gated P/Q-type C a 2 + Ca^{2+} C a 2 + channels.

Vesicle Docking & Fusion (SNARE Complex) : Inward C a 2 + Ca^{2+} C a 2 + flux binds the calcium sensor synaptotagmin-1 , which triggers immediate assembly of the core SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor) complex:

Synaptobrevin (also known as VAMP, Vesicle-Associated Membrane Protein) on the synaptic vesicle.

Syntaxin-1 and SNAP-25 (Synaptosomal-Associated Protein 25) on the presynaptic plasma membrane.

Tight zippering of the SNARE pins drives quantal exocytosis of acetylcholine (ACh) into the 20 – 50 nm 20\text{--}50\text{ nm} 20 – 50 nm synaptic cleft (roughly 5,000 to 10,000 ACh molecules per quantum/vesicle).

Postsynaptic Activation : ACh diffuses across the cleft and binds to the two α \alpha α subunits of the pentameric nicotinic acetylcholine receptor ( n A C h R nAChR n A C h R ) located on the crests of junctional folds. The adult muscle receptor has an ( α 1 ) 2 β 1 ϵ δ (\alpha_1)_2\beta_1\epsilon\delta ( α 1 ​ ) 2 ​ β 1 ​ ϵδ subunit stoichiometry. Binding opens a nonselective cation channel permeable to both N a + Na^+ N a + and K + K^+ K + .

End-Plate Potential (EPP) : Because the resting muscle potential is − 90 mV -90\text{ mV} − 90 mV (far from E N a = + 65 mV E_{Na} = +65\text{ mV} E N a ​ = + 65 mV and close to E K = − 90 mV E_K = -90\text{ mV} E K ​ = − 90 mV ), inward N a + Na^+ N a + current through the open n A C h R nAChR n A C h R channels vastly exceeds outward K + K^+ K + current. This produces a local, graded depolarization known as the End-Plate Potential (EPP) . In healthy tissue, the EPP amplitude ( 40 – 50 mV 40\text{--}50\text{ mV} 40 – 50 mV ) far exceeds the threshold required to activate voltage-gated N a v Nav N a v channels in the perijunctional muscle membrane ( high safety factor ).

Signal Termination : Acetylcholine is rapidly hydrolyzed by acetylcholinesterase (AChE) anchored to the synaptic basal lamina into acetate and choline within sub-milliseconds. Choline is recaptured by the presynaptic high-affinity choline transporter 1 (CHT1) to synthesize new ACh via choline acetyltransferase (ChAT).

Neuromuscular Transmission Disorders

Feature Myasthenia Gravis (MG) Lambert-Eaton Myasthenic Syndrome (LEMS) Botulism

Primary Pathology Autoantibodies against postsynaptic nicotinic ACh receptors ( n A C h R nAChR n A C h R ) in 85%, or anti-MuSK Autoantibodies against presynaptic P/Q-type voltage-gated C a 2 + Ca^{2+} C a 2 + channels (VGCC) Botulinum neurotoxin ( B o N T BoNT B o NT ) cleaves SNARE proteins (SNAP-25, syntaxin, synaptobrevin)

Synaptic Defect Postsynaptic: reduced functional n A C h R s nAChRs n A C h R s and simplified junctional folds Presynaptic: impaired C a 2 + Ca^{2+} C a 2 + influx, reducing quantal ACh vesicle release Presynaptic: complete blockade of ACh exocytotic machinery

Clinical Presentation Fluctuating fatiguable weakness; ptosis, diplopia, bulbar weakness; worsens with activity Proximal limb weakness; hyporeflexia, autonomic dysfunction (dry mouth, erectile failure) Descending flaccid paralysis; fixed dilated pupils, cranial nerve palsies, respiratory failure

Effect of Exertion Fatigue : Weakness worsens with repetitive exercise Facilitation : Muscle strength improves transiently after brief high-intensity contraction Progressive paralysis; no facilitation

Repetitive Nerve Stimulation (RNS) Decremental response ( > 10 % > 10\% > 10% drop in compound muscle action potential [CMAP] at low frequency 3 Hz 3\text{ Hz} 3 Hz ) Incremental response (marked CMAP amplitude increase > 100 % > 100\% > 100% following high-frequency 20 – 50 Hz 20\text{--}50\text{ Hz} 20 – 50 Hz stimulation or 10s post-exercise) Decremental or flat CMAP; no improvement

Systemic Association Thymoma ( 10 – 15 % 10\text{--}15\% 10 – 15% ) or thymic follicular hyperplasia ( 65 % 65\% 65% ) Small cell lung carcinoma (SCLC) ( 50 – 60 % 50\text{--}60\% 50 – 60% ), paraneoplastic syndrome Ingestion of preformed toxin in canned food ( Clostridium botulinum ) or infant honey spores

Pharmacotherapy Acetylcholinesterase inhibitors (pyridostigmine), immunosuppression, thymectomy Potassium channel blockers (3,4-diaminopyridine [amifampridine]), treat underlying SCLC Equine botulinum antitoxin, intensive respiratory support

Excitation-Contraction (EC) Coupling in Muscle

Excitation-contraction (EC) coupling converts an electrical membrane action potential into mechanical cross-bridge cycling and force generation. The molecular transducers vary fundamentally across skeletal, cardiac, and smooth muscle.

Skeletal Muscle EC Coupling

Sarcolemmal Invaginations : The muscle action potential propagates across the sarcolemma and plunges deep into the myofiber along Transverse Tubules (T-tubules) . T-tubules flank the terminal cisternae of the sarcoplasmic reticulum at the A-I band junction, forming triads (one central T-tubule and two adjacent SR cisternae).

Voltage-sensor (mechanical) coupling : Depolarization triggers a conformational change in the Dihydropyridine Receptor (DHPR / Cav1.1) , an L-type voltage-gated calcium channel located on the T-tubule membrane. In skeletal muscle, DHPR acts strictly as an electromechanical voltage sensor ; extracellular C a 2 + Ca^{2+} C a 2 + influx is not required.

Ryanodine Receptor Activation : Conformational shift of the cytoplasmic loop of DHPR physically pulls open the Ryanodine Receptor 1 (RyR1) foot-protein channel on the adjacent terminal cisternae.

Intracellular Calcium Surge : Massive quantities of C a 2 + Ca^{2+} C a 2 + stored within the SR bound to the low-affinity buffer protein calsequestrin rush into the myoplasm, driving free [ C a 2 + ] [Ca^{2+}] [ C a 2 + ] from 10 − 7 mol/L 10^{-7}\text{ mol/L} 1 0 − 7 mol/L to 10 − 5 mol/L 10^{-5}\text{ mol/L} 1 0 − 5 mol/L .

Troponin Complex Activation : Calcium binds to Troponin C ( T n C TnC T n C ) . This induces a conformational change across the heterotrimeric troponin complex:

Troponin I ( T n I TnI T n I ) releases its inhibitory clamp on actin.

Troponin T ( T n T TnT T n T ) shifts tropomyosin deeper into the groove of the F-actin helix, exposing the previously sterically blocked myosin-binding sites on the actin monomers.

Cross-Bridge Cycle & Power Stroke :

Rigor State : Myosin head is tightly bound to actin in the absence of ATP (rigor mortis occurs after death due to complete ATP depletion).

Detachment : A new molecule of ATP binds the nucleotide pocket of the myosin head, causing immediate allosteric dissociation from actin.

Cocking (Hydrolysis) : The intrinsic myosin ATPase hydrolyzes ATP to ADP and inorganic phosphate ( P i P_i P i ​ ), both remaining bound to the head. This rotates the myosin lever arm into a "cocked", high-energy 90-degree conformation.

Cross-Bridge Attachment : The cocked myosin head binds weakly to an exposed actin monomer.

Power Stroke : Release of inorganic phosphate ( P i P_i P i ​ ) triggers the mechanical power stroke. The myosin lever arm rotates to a 45-degree angle, pulling the thin actin filament approximately 10 nm 10\text{ nm} 10 nm toward the center of the sarcomere (M-line). Sarcomere shortening occurs: the I-band and H-zone narrow , while the A-band length remains constant .

ADP Release : ADP dissociates from the myosin head, returning it to the high-affinity rigor state awaiting another ATP.

Relaxation : Sarcoplasmic reticulum C a 2 + Ca^{2+} C a 2 + -ATPase ( SERCA1 ) pumps free cytoplasmic C a 2 + Ca^{2+} C a 2 + back into the SR lumen against a concentration gradient, allowing tropomyosin to slide back over the actin binding sites.

PLE High-Yield Point (Malignant Hyperthermia) : An autosomal dominant mutation in the R Y R 1 RYR1 R Y R 1 gene predisposes patients to uncontrolled, massive sarcoplasmic C a 2 + Ca^{2+} C a 2 + release when exposed to volatile halogenated inhalational anesthetics (halothane, isoflurane, sevoflurane) or the depolarizing muscle relaxant succinylcholine. Sustained hypermetabolism, generalized muscle rigidity, hyperkalemia, extreme hyperthermia, and metabolic acidosis ensue. The immediate antidote of choice is dantrolene , a specific RyR1 antagonist that blocks SR calcium release.

Cardiac Muscle EC Coupling

Calcium-Induced Calcium Release (CICR) : Unlike skeletal muscle, cardiac myocytes require extracellular calcium influx. The cardiac action potential plateau (Phase 2) opens L-type C a 2 + Ca^{2+} C a 2 + channels ( Cav1.2 / DHPR ), allowing inward trigger C a 2 + Ca^{2+} C a 2 + current ( I C a , L I_{Ca,L} I C a , L ​ ). This trigger C a 2 + Ca^{2+} C a 2 + binds to Ryanodine Receptor 2 (RyR2) on the SR, opening the channel to release a much larger wave of calcium into the cytoplasm ( CICR ).

Modulation by Phospholamban (PLB) : Cardiac SERCA2a is tonically inhibited by unphosphorylated phospholamban. Beta-1 adrenergic stimulation (epinephrine, norepinephrine) activates adenylyl cyclase → \rightarrow → cyclic AMP → \rightarrow → Protein Kinase A (PKA). PKA phosphorylates phospholamban, relieving its inhibitory clamp on SERCA2a. This dramatically accelerates SR C a 2 + Ca^{2+} C a 2 + reuptake, speeding myocardial relaxation ( positive lusitropy ) while increasing SR calcium load for the next beat ( positive inotropy ).

Smooth Muscle EC Coupling

Smooth muscle possesses no troponin, no T-tubules, and no striations or organized sarcomeres. Instead, actin and myosin filaments are tethered to cytoskeletal dense bodies (analogous to Z-lines) and the plasma membrane.

Calcium Entry : Cytosolic calcium rises through voltage-gated Cav1.2 channels, receptor-operated channels, or I P 3 IP_3 I P 3 ​ -mediated release from sparse SR stores following G q G_q G q ​ -coupled receptor activation.

Calmodulin Activation : C a 2 + Ca^{2+} C a 2 + binds to the ubiquitous intracellular calcium-binding protein calmodulin ( 4 C a 2 + 4\ Ca^{2+} 4 C a 2 + ions per calmodulin).

MLCK Phosphorylation : The C a 2 + Ca^{2+} C a 2 + -calmodulin complex binds and activates Myosin Light-Chain Kinase (MLCK) .

Cross-Bridge Formation : Activated MLCK phosphorylates the 20-kDa regulatory light chain of the myosin head. Phosphorylation activates myosin ATPase, allowing it to bind actin and initiate cross-bridge cycling.

Relaxation via MLCP : Dephosphorylation of the regulatory light chain by Myosin Light-Chain Phosphatase (MLCP) terminates contraction.

The Nitric Oxide / cGMP Vasodilatory Pathway : Nitric oxide (NO) diffuses from endothelial cells into vascular smooth muscle, activating soluble guanylyl cyclase → \rightarrow → cyclic GMP → \rightarrow → Protein Kinase G (PKG). PKG phosphorylates and activates MLCP, while inhibiting Cav channels and SERCA re-uptake, promoting profound smooth muscle relaxation and arteriolar vasodilation.

Latch-State Phenomenon : When myosin is dephosphorylated by MLCP while still attached to actin, the cross-bridge detaches extremely slowly. This allows vascular and visceral smooth muscle to maintain sustained, tonic wall tension for hours with minimal ongoing ATP expenditure.

Systematic Comparison of Muscle Types

  • Property Skeletal Muscle Cardiac Muscle Smooth Muscle
  • Striations & Sarcomeres Yes Yes No (dense bodies)
  • T-Tubule Structure Triads at A-I junctions Diads at Z-lines Absent (caveolae present)

Extracellular C a 2 + Ca^{2+} C a 2 + Needed for Contraction No (mechanical coupling) Yes (essential for CICR) Yes (Cav and store-operated channels)

  • Calcium Sensor Protein Troponin C ( T n C TnC T n C ) Troponin C ( T n C TnC T n C ) Calmodulin
  • Enzyme Mediating Contraction Myosin ATPase directly Myosin ATPase directly Myosin Light-Chain Kinase (MLCK)

SR Ryanodine Receptor RyR1 (coupled to Cav1.1) RyR2 (activated by trigger C a 2 + Ca^{2+} C a 2 + ) RyR3 / I P 3 IP_3 I P 3 ​ Receptor

Intercellular Gap Junctions Absent (electrically isolated fibers) Present (intercalated discs, syncytium) Present in unitary/single-unit smooth muscle

Spontaneous Pacemaker Activity None (requires motor nerve spike) Yes (SA and AV nodal tissue) Yes in unitary smooth muscle (slow waves)

Speed of Contraction Fast ( 10 – 100 ms 10\text{--}100\text{ ms} 10 – 100 ms ) Intermediate ( 200 – 400 ms 200\text{--}400\text{ ms} 200 – 400 ms ) Very slow ( 1 – 3 s 1\text{--}3\text{ s} 1 – 3 s , latch-state)

Motor units and muscle fiber types

A motor unit is one alpha motor neuron plus all the muscle fibers it supplies. Units are recruited from small to large (Henneman's size principle), so fine movements use small units first.

Type I (slow-twitch, red) fibers are oxidative, rich in myoglobin and mitochondria, and fatigue-resistant. Postural muscles such as the soleus are rich in them.

Type II (fast-twitch, white) fibers are glycolytic, fast and fatigable.

Force also depends on starting length: the length-tension relationship peaks at the sarcomere length that gives optimal actin-myosin overlap. The same principle underlies the Frank-Starling law of the heart.

Loading diagram... Neuromuscular Junction Transmission and Skeletal Muscle Excitation-Contraction Coupling